Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12620000639921
Ethics application status
Approved
Date submitted
8/05/2020
Date registered
1/06/2020
Date last updated
30/08/2022
Date data sharing statement initially provided
1/06/2020
Type of registration
Prospectively registered
Titles & IDs
Public title
Characterising Left Atrial Function and Compliance in Atrial Fibrillation
Query!
Scientific title
The Impact of Left Atrial Function and Compliance in patients with paroxysmal and persistent Atrial Fibrillation undergoing Catheter Ablation
Query!
Secondary ID [1]
301086
0
Nil Known
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Atrial Fibrillation
317156
0
Query!
Condition category
Condition code
Cardiovascular
315305
315305
0
0
Query!
Other cardiovascular diseases
Query!
Intervention/exposure
Study type
Observational
Query!
Patient registry
False
Query!
Target follow-up duration
Query!
Target follow-up type
Query!
Description of intervention(s) / exposure
All patients recruited to the study will have symptomatic atrial fibrillation (AF) planned for AF ablation. AF ablation is an interventional treatment for AF recommended for patients with symptomatic AF refractory to at least 1 anti-arrhythmic drug. Participants will be recruited when both patient and physician have decided to proceed with AF ablation. These patients will undergo AF ablation regardless of recruitment to the study.
Within 4 weeks prior to their AF ablation, enrolled participants will undergo a series of non-invasive testing including baseline echocardiogram, stress echocardiogram, cardiopulmonary exercise testing and blood sampling for NT-pro BNP. They will also complete an AF symptom questionnaire and the Minnesota Living with Heart Failure questionnaire.
AF ablation will then be undertaken as per standard institutional protocols. LA pressure will be
measured via trans-septal puncture, as occurs routinely during such procedures. LA dimensions will be measured by transoesopageal echocardiography (TOE). TOE is also part of the standard procedure to exclude left atrial thrombus and guide transeptal puncture. Following baseline assessment of LA dimensions and LA pressure, the LA will be directly infused with isotonic saline through the standard LA sheath. The volume to be infused will be 15 mL/kg of body weight over 8 minutes. LA volume via TTE and LA pressure will be recorded every 2 minutes during the infusion using TTE. During infusion, LA pressure and respiratory parameters will be measured and infusion will be stopped if there is any evidence of fluid overload. LA compliance will be calculated from the LA volume pressure curve provided by these measurements.
Procedure duration will be variable depending on the ablation procedure itself and can last anywhere between 1-4 hours. The study protocol will add only 10 minutes to the overall procedure. Following the procedure, patients will be followed up for a period of 12 months and in addition to standard follow-up protocols, will undergo repeat stress echocardiogram and CPET and 6 and 12 months post-procedure.
Query!
Intervention code [1]
317394
0
Not applicable
Query!
Comparator / control treatment
Within the recruited cohort, comparisons will be made between participants with persistent and paroxysmal AF.
Query!
Control group
Active
Query!
Outcomes
Primary outcome [1]
323546
0
Left atrial stiffness assessed by measuring left atrial pressure changes with direct infusion of isotonic saline into the left atrium. Left atrial pressure will be assessed by using the standard pressure transducer used for transeptal puncture during the AF ablation procedure.
Query!
Assessment method [1]
323546
0
Query!
Timepoint [1]
323546
0
At the time of catheter ablation
Query!
Secondary outcome [1]
382207
0
Left atrial dimensions assessed using transthoracic echocardiography.
Query!
Assessment method [1]
382207
0
Query!
Timepoint [1]
382207
0
Within 4 weeks prior to AF ablation procedure
Query!
Secondary outcome [2]
382209
0
Left atrial ejection fraction using transthoracic echocardiography
Query!
Assessment method [2]
382209
0
Query!
Timepoint [2]
382209
0
Within 4 weeks prior to AF ablation
Query!
Secondary outcome [3]
382212
0
Left ventricular global longitudinal strain assessed using transthoracic echocardiography
Query!
Assessment method [3]
382212
0
Query!
Timepoint [3]
382212
0
Within 4 weeks prior to AF ablation
Query!
Secondary outcome [4]
382213
0
Symptoms of atrial fibrillation using AF symptom severity (AFSS) questionnaire score
Query!
Assessment method [4]
382213
0
Query!
Timepoint [4]
382213
0
Prior to AF ablation and 12 months after ablation
Query!
Secondary outcome [5]
382214
0
Minnesota Living with Heart Failure Questionnaire score
Query!
Assessment method [5]
382214
0
Query!
Timepoint [5]
382214
0
4 weeks prior to AF ablation and 12 months after ablation
Query!
Secondary outcome [6]
382215
0
Aerobic exercise capacity using the 6 minute walk test.
Query!
Assessment method [6]
382215
0
Query!
Timepoint [6]
382215
0
Within 4 weeks prior to AF ablation and 12 months after AF ablation
Query!
Secondary outcome [7]
382216
0
Exercise capacity assessed using Peak VO2 measured during cardiopulmonary exercise test
Query!
Assessment method [7]
382216
0
Query!
Timepoint [7]
382216
0
4 weeks prior to AF ablation and 12 months after AF ablation
Query!
Secondary outcome [8]
382217
0
Left ventricular diastolic function during exercise with cycle ergometer exercise stress echocardiogram (E/e' and TR velocity)
Query!
Assessment method [8]
382217
0
Query!
Timepoint [8]
382217
0
Within 4 weeks prior to AF ablation and 12 months after AF ablation
Query!
Secondary outcome [9]
382218
0
Pulmonary capillary wedge pressure assessed using Swan-Ganz catheter
Query!
Assessment method [9]
382218
0
Query!
Timepoint [9]
382218
0
During AF ablation procedure
Query!
Secondary outcome [10]
382219
0
AF ablation success/failure with Holter monitor or implantable cardiac device monitoring assessing for AF recurrence
Query!
Assessment method [10]
382219
0
Query!
Timepoint [10]
382219
0
3,6 and 12 months following AF ablation
Query!
Secondary outcome [11]
382220
0
Natriuretic peptides assessed using blood sampling (BNP and nt-pro-BNP)
Query!
Assessment method [11]
382220
0
Query!
Timepoint [11]
382220
0
Within 4 weeks prior to AF ablation
Query!
Secondary outcome [12]
382223
0
Composite of markers of thrombogenesis via blood sampling from the left atrium, right atrium and peripheral circulation:
Platelet activation
Thrombin generation
Endothelial dysfunction
Platelet derived inflammation
Query!
Assessment method [12]
382223
0
Query!
Timepoint [12]
382223
0
At time of AF ablation procedure
Query!
Secondary outcome [13]
382224
0
Left and right atrial voltage assessed using electroanatomic mapping catheters
Query!
Assessment method [13]
382224
0
Query!
Timepoint [13]
382224
0
At time of AF ablation
Query!
Secondary outcome [14]
383141
0
Left ventricular systolic function (ejection fraction measured using Simpson's biplane method not transthoracic echocardiography)
Query!
Assessment method [14]
383141
0
Query!
Timepoint [14]
383141
0
Within 4 weeks prior to AF ablation
Query!
Secondary outcome [15]
383142
0
Left ventricular diastolic function using transthoracic echocardiography
Query!
Assessment method [15]
383142
0
Query!
Timepoint [15]
383142
0
Within 4 weeks prior to AF ablation
Query!
Secondary outcome [16]
383148
0
Left atrial strain and strain rate assessed using transthoracic echocardiography
Query!
Assessment method [16]
383148
0
Query!
Timepoint [16]
383148
0
Within 4 weeks prior to AF ablation
Query!
Secondary outcome [17]
383149
0
Left and right atrial conduction velocity assessed using electroanatomic mapping catheters
Query!
Assessment method [17]
383149
0
Query!
Timepoint [17]
383149
0
At time of AF ablation
Query!
Secondary outcome [18]
383150
0
Atrial effective refractory periods assessed using standard electrophysiologiocal diagnostic catheters
Query!
Assessment method [18]
383150
0
Query!
Timepoint [18]
383150
0
At time of AF ablation
Query!
Secondary outcome [19]
383151
0
Sinus node recovery time assessed using standard electrophysiologiocal diagnostic catheters
Query!
Assessment method [19]
383151
0
Query!
Timepoint [19]
383151
0
At time of AF ablation
Query!
Secondary outcome [20]
413432
0
We will assess the prevalence of HFpEF in this cohort of patients with atrial fibrillation, diagnosing HFpEF when mean left atrial pressure is greater than 15mmHg at baseline. We will compare all the above paramters of left atrial function and hemodynamics between patients with HFpEF and without HFpEF.
Query!
Assessment method [20]
413432
0
Query!
Timepoint [20]
413432
0
Diagnosis of HFpEF will be made at AF ablation procedure
Query!
Eligibility
Key inclusion criteria
Symptomatic AF with scheduled AF ablation procedure and failed >1 antiarrhythmic drug therapy
Capable of providing written consent
Ability to perform an exercise stress test on a cycle ergometer
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Ejection fraction <50% by transthoracic echocardiography (TTE) determined by Simpsons biplane method at the time of enrolment
Previous diagnosis of a cardiopmyopathy
Moderate to severe valvulopathy
Prior diagnosis of pulmonary hypertension
Active malignancy
Musculoskeletal diseases or injuries limiting exercise capacity
Severe chronic obstructive pulmonary disease
Moderate to severe valvulopathy
Unable to provide written consent
Unable to exercise
Query!
Study design
Purpose
Natural history
Query!
Duration
Longitudinal
Query!
Selection
Defined population
Query!
Timing
Prospective
Query!
Statistical methods / analysis
A previous study has reported that mean LA stiffness is 0.5mmhg/ml in a cohort of patients with paroxysmal AF. In order to detect a 0.3mmHg/ml difference in LA stiffness between patients with paroxysmal and persistent AF with 80% power, we would require a total of 29 patients in each group.
Early data after recruitment of 40 patients showed that 50% of patients with AF have raised LA pressure at baseline and therefore have a diagnosis of HFpEF. We would like to compare AF patients with paroxysmal AF with those with those with persistent AF. The primary outcome is change in left atrial compliance which is calculated by dividing change in left atrial diameter by change in left atrial pressure with saline infusion. Our data so far shows that the ratio of change in diameter to change in pressure in paroxysmal AF is 220 compared to 250 (standard deviation 70) in persistent AF. In order to observe a significant difference between the 2 groups with 80% and alpha error of 0.5, we will need a total of 85 patients in each group.
We have also powered the study to assess the prevalence of HFpEF in this cohort of patients with AF. We calculated that a sample size of 93 would be required to determine a prevalence of 40% with a desired precision of ±10% at the 95% confidence level.
Query!
Recruitment
Recruitment status
Recruiting
Query!
Date of first participant enrolment
Anticipated
1/06/2020
Query!
Actual
1/06/2020
Query!
Date of last participant enrolment
Anticipated
31/12/2022
Query!
Actual
Query!
Date of last data collection
Anticipated
2/01/2023
Query!
Actual
Query!
Sample size
Target
170
Query!
Accrual to date
115
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
SA
Query!
Recruitment hospital [1]
16516
0
The Royal Adelaide Hospital - Adelaide
Query!
Recruitment hospital [2]
16518
0
Ashford Community Hospital - Ashford
Query!
Recruitment postcode(s) [1]
30072
0
5000 - Adelaide
Query!
Recruitment postcode(s) [2]
30074
0
5035 - Ashford
Query!
Funding & Sponsors
Funding source category [1]
305522
0
Hospital
Query!
Name [1]
305522
0
In-kind support from Centre for Heart Rhythm Disorders, Royal Adelaide Hospital
Query!
Address [1]
305522
0
Centre for Heart Rhythm Disorders,
Royal Adelaide Hospital,
Adelaide 5000
South Australia
Query!
Country [1]
305522
0
Australia
Query!
Primary sponsor type
University
Query!
Name
University of Adelaide
Query!
Address
University of Adelaide,
Adelaide, 5005
South Australia
Query!
Country
Australia
Query!
Secondary sponsor category [1]
305932
0
None
Query!
Name [1]
305932
0
Query!
Address [1]
305932
0
Query!
Country [1]
305932
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
305834
0
Central Adelaide Local Health Network Human Research Ethics Committee
Query!
Ethics committee address [1]
305834
0
Royal Adelaide Hospital
Clinical Trial Centre
Level 3, Wayfinder 3D460.02
Port Road
ADELAIDE SA 5000
Query!
Ethics committee country [1]
305834
0
Australia
Query!
Date submitted for ethics approval [1]
305834
0
Query!
Approval date [1]
305834
0
15/10/2019
Query!
Ethics approval number [1]
305834
0
Query!
Summary
Brief summary
This study will investigate the association between left atrial compliance on AF type (paroxysmal versus persistent), patient symptoms, exercise tolerance, left ventricular function and long-term prognosis. The hypothesis is that left atrial compliance will be increased in patients with persistent AF compared with those with paroxysmal AF and may be correlated with patient symptoms, exercise tolerance and long-term outcomes of AF ablation. This will be the first study to assess left atrial compliance using direct measurements of the left atrial dimensions and pressure and direct infusion of saline into the left atrium.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
101758
0
Prof Prash Sanders
Query!
Address
101758
0
Centre for Heart Rhythm Disorders | University of Adelaide
Cardiovascular Investigation Unit | Royal Adelaide Hospital
Adelaide SA 5000
Australia
Query!
Country
101758
0
Australia
Query!
Phone
101758
0
+61 883139000
Query!
Fax
101758
0
Query!
Email
101758
0
[email protected]
Query!
Contact person for public queries
Name
101759
0
Miss Ellen Lyrtzis
Query!
Address
101759
0
South Australian Health and Medical Research Institute
PO Box 11060
Adelaide 5001
South Australia
Query!
Country
101759
0
Australia
Query!
Phone
101759
0
+61 8 8128 4000
Query!
Fax
101759
0
Query!
Email
101759
0
[email protected]
Query!
Contact person for scientific queries
Name
101760
0
Dr Adrian Elliott
Query!
Address
101760
0
Centre for Heart Rhythm Disorders | University of Adelaide
Cardiovascular Investigation Unit | Royal Adelaide Hospital
Adelaide SA 5000
Australia
Query!
Country
101760
0
Australia
Query!
Phone
101760
0
+61 883139000
Query!
Fax
101760
0
Query!
Email
101760
0
[email protected]
Query!
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
Query!
No/undecided IPD sharing reason/comment
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
Source
Title
Year of Publication
DOI
Embase
Identification of Subclinical Heart Failure With Preserved Ejection Fraction in Patients With Symptomatic Atrial Fibrillation.
2023
https://dx.doi.org/10.1016/j.jchf.2023.07.019
Embase
Exercise echocardiography to assess left atrial function in patients with symptomatic AF.
2024
https://dx.doi.org/10.1016/j.ijcha.2023.101324
N.B. These documents automatically identified may not have been verified by the study sponsor.
Download to PDF